Team:Goettingen/project overview/project

From 2014.igem.org

(Difference between revisions)
m
m
Line 43: Line 43:
<!-- right column-->
<!-- right column-->
<div class="proRP" id="rpart1">
<div class="proRP" id="rpart1">
-
<div id="goenext"><a href="https://2014.igem.org/Team:Goettingen/project_overview/current_tools"><img src='https://static.igem.org/mediawiki/2014/3/32/Goettingen2014-previous.png' width='50px'></a> 4/11 <a href="https://2014.igem.org/Team:Goettingen/project_overview/perspectives"><img src='https://static.igem.org/mediawiki/2014/e/ea/Goettingen2014-next.png' width='50px'></a></div><br />
+
        <div id="goenext"><a href="https://2014.igem.org/Team:Goettingen/project_overview/current_tools"><img src='https://static.igem.org/mediawiki/2014/3/32/Goettingen2014-previous.png' width='40px'></a> 4/11 <a href="https://2014.igem.org/Team:Goettingen/project_overview/perspectives"><img src='https://static.igem.org/mediawiki/2014/e/ea/Goettingen2014-next.png' width='40px'></a></div><br />
       <h1 >Our project!</h1>
       <h1 >Our project!</h1>
       <br />
       <br />
Line 81: Line 81:
}(document, 'script', 'facebook-jssdk'));</script>
}(document, 'script', 'facebook-jssdk'));</script>
<br /><br />
<br /><br />
 +
        <div id="goenext"><a href="https://2014.igem.org/Team:Goettingen/project_overview/current_tools"><img src='https://static.igem.org/mediawiki/2014/3/32/Goettingen2014-previous.png' width='40px'></a> 4/11 <a href="https://2014.igem.org/Team:Goettingen/project_overview/perspectives"><img src='https://static.igem.org/mediawiki/2014/e/ea/Goettingen2014-next.png' width='40px'></a></div><br />
 +
<div class="fb-like" data-layout="standard" data-action="like" data-show-faces="true" data-share="true"></div>
<div class="fb-like" data-layout="standard" data-action="like" data-show-faces="true" data-share="true"></div>
<script>
<script>

Revision as of 11:05, 15 September 2014

4/11

Our project!


Paving the way for new diagnostic and therapeutic tools

Our aim is to develop a diagnostic technique capable of detecting the presence of fungal pathogens in a sample collected from a patient. Briefly, our approach is as follows. Through a yeast two-hybrid assay we will select a set of peptides that show affinity towards surface proteins from different fungi (Aspergillus nidulans, A. fumigatus, Candida albicans and C. glabrata). After confirming the interaction between the surface proteins and a given peptide, we intend to attach a molecule to the peptide marker. In our project, this molecule will be a fluorescent protein, but in principle can also be an immune system activator which is then recognized by the immune cells or other chemical moiety that adds novel functionalities or increases the peptide stability.


Why peptides?

In comparison to antibodies or antibody fragments, peptides are small, easily synthesized, modified less expensively and show higher diffusion rates in tissues. We expect our method to be more accurate and cheaper than other existing methods. We also expect it to have the potential for in vivo diagnosis. Furthermore, the adaptability of our approach allow other laboratories to follow it to generate and refine their own peptides with specificity towards their proteins of interest.




4/11